<?xml version='1.0' encoding='utf-8'?>
<document id="29989304"><sentence text="In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation."><entity charOffset="78-90" id="DDI-PubMed.29989304.s1.e0" text="itraconazole" /><entity charOffset="95-105" id="DDI-PubMed.29989304.s1.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.29989304.s1.e0" e2="DDI-PubMed.29989304.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s1.e0" e2="DDI-PubMed.29989304.s1.e1" /></sentence><sentence text="The magnitude of interaction between the CYP3A4 substrate tacrolimus and various CYP3A4 inhibitors is highly unpredictable"><entity charOffset="58-68" id="DDI-PubMed.29989304.s2.e0" text="tacrolimus" /></sentence><sentence text=" We investigated whether an individual's baseline in vivo CYP3A4 activity, assessed using the oral midazolam (MDZ) probe, could be used to predict the magnitude of drug-drug interaction between tacrolimus and the potent CYP3A4 inhibitor itraconazole"><entity charOffset="99-108" id="DDI-PubMed.29989304.s3.e0" text="midazolam" /><entity charOffset="110-113" id="DDI-PubMed.29989304.s3.e1" text="MDZ" /><entity charOffset="194-204" id="DDI-PubMed.29989304.s3.e2" text="tacrolimus" /><entity charOffset="237-249" id="DDI-PubMed.29989304.s3.e3" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e0" e2="DDI-PubMed.29989304.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e0" e2="DDI-PubMed.29989304.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e0" e2="DDI-PubMed.29989304.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e0" e2="DDI-PubMed.29989304.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e1" e2="DDI-PubMed.29989304.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e1" e2="DDI-PubMed.29989304.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e1" e2="DDI-PubMed.29989304.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e2" e2="DDI-PubMed.29989304.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s3.e2" e2="DDI-PubMed.29989304.s3.e3" /></sentence><sentence text=" In a prospective single-arm open-label study, 16 healthy volunteers were administered single doses of MDZ and tacrolimus before and after a 4-day course of itraconazole"><entity charOffset="111-121" id="DDI-PubMed.29989304.s4.e0" text="tacrolimus" /><entity charOffset="157-169" id="DDI-PubMed.29989304.s4.e1" text="itraconazole" /><entity charOffset="103-114" id="DDI-PubMed.29989304.s4.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.29989304.s4.e2" e2="DDI-PubMed.29989304.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s4.e2" e2="DDI-PubMed.29989304.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s4.e2" e2="DDI-PubMed.29989304.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s4.e0" e2="DDI-PubMed.29989304.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s4.e0" e2="DDI-PubMed.29989304.s4.e1" /></sentence><sentence text=" Itraconazole treatment resulted in a 9"><entity charOffset="1-13" id="DDI-PubMed.29989304.s5.e0" text="Itraconazole" /></sentence><sentence text="0-fold decrease in MDZ apparent oral clearance (CL/F) and a 3"><entity charOffset="19-30" id="DDI-PubMed.29989304.s6.e0" text="MDZ" /></sentence><sentence text="3-fold decrease in tacrolimus CL/F (P &lt; 0"><entity charOffset="33-34" id="DDI-PubMed.29989304.s7.e0" text="F" /></sentence><sentence text="001 for each)" /><sentence text=" MDZ CL/F and tacrolimus CL/F were positively correlated both at baseline (r = 0"><entity charOffset="8-9" id="DDI-PubMed.29989304.s9.e0" text="F" /><entity charOffset="14-24" id="DDI-PubMed.29989304.s9.e1" text="tacrolimus" /><entity charOffset="28-29" id="DDI-PubMed.29989304.s9.e2" text="F" /><entity charOffset="1-1" id="DDI-PubMed.29989304.s9.e3" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e3" e2="DDI-PubMed.29989304.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e3" e2="DDI-PubMed.29989304.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e3" e2="DDI-PubMed.29989304.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e3" e2="DDI-PubMed.29989304.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e0" e2="DDI-PubMed.29989304.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e0" e2="DDI-PubMed.29989304.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e0" e2="DDI-PubMed.29989304.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e1" e2="DDI-PubMed.29989304.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s9.e1" e2="DDI-PubMed.29989304.s9.e2" /></sentence><sentence text="582, P = 0" /><sentence text="018) and after itraconazole (r = 0"><entity charOffset="15-27" id="DDI-PubMed.29989304.s11.e0" text="itraconazole" /></sentence><sentence text="811, P &lt; 0" /><sentence text="001)" /><sentence text=" Furthermore, baseline MDZ CL/F was positively correlated to the fold change in MDZ CL/F resulting from CYP3A4 inhibition (r = 0"><entity charOffset="23-34" id="DDI-PubMed.29989304.s14.e0" text="MDZ" /><entity charOffset="80-91" id="DDI-PubMed.29989304.s14.e1" text="MDZ" /><entity charOffset="1-12" id="DDI-PubMed.29989304.s14.e2" text="F" /><entity charOffset="30-41" id="DDI-PubMed.29989304.s14.e3" text="F" /><entity charOffset="87-98" id="DDI-PubMed.29989304.s14.e4" text="F" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e2" e2="DDI-PubMed.29989304.s14.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e2" e2="DDI-PubMed.29989304.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e2" e2="DDI-PubMed.29989304.s14.e3" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e2" e2="DDI-PubMed.29989304.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e2" e2="DDI-PubMed.29989304.s14.e4" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e0" e2="DDI-PubMed.29989304.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e0" e2="DDI-PubMed.29989304.s14.e3" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e0" e2="DDI-PubMed.29989304.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e0" e2="DDI-PubMed.29989304.s14.e4" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e3" e2="DDI-PubMed.29989304.s14.e3" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e3" e2="DDI-PubMed.29989304.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e3" e2="DDI-PubMed.29989304.s14.e4" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e1" e2="DDI-PubMed.29989304.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s14.e1" e2="DDI-PubMed.29989304.s14.e4" /></sentence><sentence text="759, P = 0" /><sentence text="001)" /><sentence text=" However, no predictors of change in tacrolimus CL/F resulting from CYP3A4 inhibition were identified, including baseline MDZ CL/F (P = 0"><entity charOffset="129-130" id="DDI-PubMed.29989304.s17.e0" text="F" /><entity charOffset="122-122" id="DDI-PubMed.29989304.s17.e1" text="MDZ" /><entity charOffset="51-51" id="DDI-PubMed.29989304.s17.e2" text="F" /><pair ddi="false" e1="DDI-PubMed.29989304.s17.e2" e2="DDI-PubMed.29989304.s17.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s17.e2" e2="DDI-PubMed.29989304.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s17.e2" e2="DDI-PubMed.29989304.s17.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s17.e1" e2="DDI-PubMed.29989304.s17.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s17.e1" e2="DDI-PubMed.29989304.s17.e0" /></sentence><sentence text="453), baseline tacrolimus CL/F (P = 0"><entity charOffset="29-30" id="DDI-PubMed.29989304.s18.e0" text="F" /></sentence><sentence text="759) and fold change in MDZ CL/F between both phases (P = 0"><entity charOffset="24-24" id="DDI-PubMed.29989304.s19.e0" text="MDZ" /><entity charOffset="31-31" id="DDI-PubMed.29989304.s19.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.29989304.s19.e0" e2="DDI-PubMed.29989304.s19.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s19.e0" e2="DDI-PubMed.29989304.s19.e1" /></sentence><sentence text="274)" /><sentence text=" In conclusion, baseline oral MDZ clearance does not predict the magnitude of interaction between tacrolimus and itraconazole"><entity charOffset="98-108" id="DDI-PubMed.29989304.s21.e0" text="tacrolimus" /><entity charOffset="113-125" id="DDI-PubMed.29989304.s21.e1" text="itraconazole" /><entity charOffset="30-41" id="DDI-PubMed.29989304.s21.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.29989304.s21.e2" e2="DDI-PubMed.29989304.s21.e2" /><pair ddi="false" e1="DDI-PubMed.29989304.s21.e2" e2="DDI-PubMed.29989304.s21.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s21.e2" e2="DDI-PubMed.29989304.s21.e1" /><pair ddi="false" e1="DDI-PubMed.29989304.s21.e0" e2="DDI-PubMed.29989304.s21.e0" /><pair ddi="false" e1="DDI-PubMed.29989304.s21.e0" e2="DDI-PubMed.29989304.s21.e1" /></sentence><sentence text="" /></document>